Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor, primarily indicated for the treatment of ALK-positive locally a···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：10
Lorlatinib is a third-generation dual-target inhibitor of ALK/ROS1, primarily indicated for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC). It is particu···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：11
The price of lorlatinib varies significantly, mainly depending on the drug source (innovator or generic), availability of medical insurance reimbursement, and purchase channel.Late···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：10
This drug is a prescription medicine. Its use must strictly follow the doctor’s instructions, and it shall not be purchased or dosed without authorization.What is the price of one ···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：10
The price of Lorlatinib is subject to significant fluctuations due to the impacts of regions, purchase channels, dosage specifications, and medical insurance policies.What is the P···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：10
The monthly treatment cost of lorlatinib currently available in China fluctuates according to specifications and regional differences, and may change in the future with the adjustm···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：12
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the targeted anticancer therapy Lorbrena (lor···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：12
On March 3, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental New Drug Application (sNDA) for Lorbrena (lorlatinib), expanding i···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：15
At the Presidential Symposium of the 2020 ESMO Annual Congress, results of a head-to-head study comparing lorlatinib versus crizotinib as first-line therapy for advanced ALK-positi···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：10
In December 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Lorbrena (lorlatinib) for the first-line treatment of patients···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：12
Pfizer recently announced that the Phase III CROWN study, which evaluates Lorbrena (lorlatinib) as a first-line treatment for patients with advanced anaplastic lymphoma kinase (ALK···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：14
Lorbrena (generic name: Lorlatinib) is a next-generation tyrosine kinase inhibitor specifically developed to combat tumors that have developed resistance to other ALK inhibitors, w···【more】
Article source：Captain MedicineRelease date：2026-01-23Recommended：11
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：662025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3642024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：732025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：882025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：912025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
